<DOC>
	<DOCNO>NCT00956202</DOCNO>
	<brief_summary>The purpose study generate data immunogenicity safety monovalent H1N1 vaccine support development registration . Primary objective : - To describe immune response vaccine 21 day vaccination participant . - To describe antibody persistence eight month first vaccine administration use HAI method , subset participant receive two injection . - To describe immune response A/H1N1 strain use HAI method 21 day vaccination 2010-2011 NH seasonal TIV administer approximately 13 month first vaccination subset participant receive two injection . - To describe safety profile vaccine participant .</brief_summary>
	<brief_title>A Study Inactivated Swine-Origin A/H1N1 Influenza Vaccines Healthy European Subjects Aged 3 17 Years</brief_title>
	<detailed_description>All participant receive two injection randomized vaccine Day 0 Day 21 , respectively . A subset child adolescent participant eligible antibody persistence evaluation sample 8 month first vaccination , also propose receive 2010-2011 Northern Hemisphere ( NH ) seasonal Trivalent Influenza Vaccine ( TIV ) 13 month first vaccination . Immunogenicity response evaluate vaccination 21 day vaccination TIV , respectively .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Inclusion Criteria : All subject : Provision Informed Consent Form sign subject 's parent ( ) /legal representative ( independent witness require local regulation ) . In addition , provision Assent Form sign subject age 8 12 year , Informed Consent Form sign subject &gt; 12 year . Subject parent/guardian able attend schedule visit comply trial procedure Subjects age 12 17 year : Aged 12 17 year day inclusion For female childbearing potential , use effective method contraception abstinence least 4 week prior first vaccination , least 4 week last vaccination . Subjects age 3 11 year : Aged 3 11 year day inclusion At Visit 05 ( Month 8 ) , antibody persistence assessment : Having receive two injection 15 µg HA vaccine ( Group 1 ) 3.8 µg HA + AF03 vaccine ( Group 2 ) Addendum 1 Informed Consent Form sign subject 's parent ( ) /guardian ( ) ( independent witness require local regulation ) . In addition , provision addendum 1 Assent Form sign subject age 6 11 year , addendum 1 Informed Consent Form sign subject ≥ 12 year . At Visit 06 , participant eligible Antibody persistence evaluation receive 20102011 Northern Hemisphere ( NH ) seasonal Trivalent Influenza Vaccine : Addendum 2 Informed Consent Form sign subject and/or subject 's parent ( ) /guardian ( ) ( independent witness require local regulation ) . In addition , provision addendum 2 Assent Form sign subject age 6 11 year , addendum 2 Informed Consent Form sign subject ≥ 12 year . All subject : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine prior Day 42 blood sample Receipt blood bloodderived product past 3 month might interfere assessment immune response Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B antigen , Hepatitis C report parents/legal representative Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Thrombocytopenia contraindicate intramuscular ( IM ) vaccination report parents/legal representative Bleeding disorder receipt anticoagulants 3 week precede inclusion contraindicate IM vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Chronic illness opinion Investigator , stage might interfere trial conduct completion Employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member employee Investigator Previous participation trial investigate vaccine swineorigin A/H1N1 influenza strain Confirmed infection swineorigin A/H1N1 influenza strain ( different seasonal strain ) 2009 Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment Receipt allergy shot and/or seasonal allergy medication 7day period prior enrollment ( vaccination ) , schedule receive allergy shot and/or seasonal allergy medication 7day period enrollment ( vaccination ) Subjects age 12 17 year : Known pregnancy , positive urine pregnancy test Currently breastfeed child Current alcohol abuse drug addiction might interfere ability comply trial procedure At Visit 05 ( Month 8 ) , antibody persistence assessment : Subjects receive , context pandemic immunization program , another A/H1N1 pandemic influenza vaccine Investigational Medicinal Products .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemic Flu</keyword>
	<keyword>Swine-origin A/H1N1 Influenza</keyword>
	<keyword>Inactivated split-virion vaccine</keyword>
	<keyword>Adjuvant</keyword>
</DOC>